Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7575186 | 1.00 | KDM4E (0.56) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL7570254 | 1.00 | KDM4E (0.56) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL7590355 | 0.84 | — | — | |
| SCHEMBL7572036 | 0.84 | KDM4E (0.50) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL7572032 | 0.81 | KDM4E (0.64) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL7570251 | 0.81 | KDM4E (0.52) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9838111 | 0.76 | KDM4E (0.52) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9499542 | 0.76 | KDM4E (0.64) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9498007 | 0.76 | KDM4E (0.64) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL9497942 | 0.76 | KDM4E (0.64) | KDM4ETP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | KDM4E 2451/4885TP53 1363/4885CYP3A4 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.